Olfactory and gustatory function impairment in COVID-19 patients : Italian objective multicenter-study by L. Angelo Vaira et al.
S P E C I A L I S S U E
Olfactory and gustatory function impairment in COVID-19
patients: Italian objective multicenter-study
Luigi Angelo Vaira MD1 | Claire Hopkins FRSC (ORLHNS), DM (Oxon)2 |
Giovanni Salzano MD3 | Marzia Petrocelli MD4 | Andrea Melis MD5 |
Marco Cucurullo MD6 | Mario Ferrari MD6 | Laura Gagliardini MD7 |
Carlotta Pipolo MD7 | Giovanna Deiana MD8 | Vito Fiore MD9 |
Andrea De Vito MD9 | Nicola Turra MD5 | Sara Canu MD10 |
Angelantonio Maglio MD11 | Antonello Serra MD12 | Francesco Bussu MD5 |
Giordano Madeddu MD9 | Sergio Babudieri MD9 |
Alessandro Giuseppe Fois MD10 | Pietro Pirina MD10 |
Francesco A. Salzano MD13 | Pierluigi De Riu MD14 | Federico Biglioli MD6 |
Giacomo De Riu MD, FEBOMFS1
1Maxillofacial Surgery Operative Unit, University Hospital of Sassari, Sassari, Italy
2King's College, London, UK
3Maxillofacial Surgery Unit, University Hospital of Naples “Federico II”, Naples, Italy
4Maxillofacial Surgery Operative Unit; Bellaria and Maggiore Hospital, AUSL, Bologna, Italy
5Otolaryngology Operative Unit, University Hospital of Sassari, Sassari, Italy
6Maxillofacial Surgery Department, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy
7Otolaryngology Operative Unit, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy
8Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
9Infectious Diseases Operative Unit, University Hospital of Sassari, Sassari, Italy
10Respiratory Diseases Operative Unit, University Hospital of Sassari, Sassari, Italy
11Respiratory Diseases Operative Unit, Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi,
Salerno, Italy
12Surveillance and Prevention Department, University Hospital of Sassari, Sassari, Italy
13Otolaryngology Operative Unit, Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi,
Salerno, Italy
14University of Turin, Turin, Italy
Correspondence
Luigi A. Vaira, Maxillofacial Surgery
Operative Unit, University Hospital of




Background: Objective data on chemosensitive disorders during COVID-19
are lacking in the Literature.
Methods: Multicenter cohort study that involved four Italian hospitals. Three
hundred and forty-five COVID-19 patients underwent objective chemosensitive
evaluation.
Results: Chemosensitive disorders self-reported by 256 patients (74.2%) but
the 30.1% of the 89 patients who did not report dysfunctions proved objectively
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hyposmic. Twenty-five percentage of patients were seen serious long-lasting
complaints. All asymptomatic patients had a slight lowering of the olfactory
threshold. No significant correlations were found between the presence and
severity of chemosensitive disorders and the severity of the clinical course. On
the contrary, there is a significant correlation between the duration of the
olfactory and gustatory symptoms and the development of severe COVID-19.
Conclusions: Patients under-report the frequency of chemosensitive disor-
ders. Contrary to recent reports, such objective testing refutes the proposal that
the presence of olfactory and gustatory dysfunction may predict a milder
course, but instead suggests that those with more severe disease neglect such
symptoms in the setting of severe respiratory disease.
KEYWORD S
ageusia, anosmia, COVID-19, smell, taste
1 | INTRODUCTION
Both its high pathogenicity and easy person-to-person
transmission have allowed SARS-CoV-2 to spread rapidly
worldwide.1 Moreover, asymptomatic and paucisymptomatic
patients, which represent up to four fifths of cases, facilitate
silent transmission.2 The identification and isolation of these
patients is therefore essential to slow down the chain of
infection. To achieve this goal, it is mandatory to establish
what the most frequent signs and symptoms may be in the
early stages of the disease or in paucisymptomatic patients.
Olfactory and gustatory disturbances were reported as
a rare clinical finding in Chinese case series on COVID-19,
affecting only 5% of the patients.3 On the contrary, since
the first outbreaks of the epidemic in Europe, we realized
that these disorders were reported by many more COVID-19
patients.4 In the past few weeks, several authors have
reported similar findings.5-10 In particular, these symp-
toms seem to be common in the early stages of the disease
and in paucisymptomatic patients.11 However, all these
reports are anamnestic or observational while the litera-
ture lacks objective studies that evaluate the gustatory
and olfactory function in these patients. Objective evalu-
ation with validated, repeatable and standardized tests is
crucial to establish exactly what the frequency, extent,
clinical characteristics of these disorders are and then
monitor their course over time. Moreover, understanding
mechanisms of sensorineural olfactory and gustatory loss
with SARS-CoV-2 infections might provide novel insights
into aspects of viral pathogenesis.
Psychophysical tests represent one of the cornerstone
in the evaluation of chemosensitive functions.12 Using
this test methodology, we recently published a prelimi-
nary study on a restricted series of hospitalized patients
objectively assessed at the University Hospital of Sas-
sari.13 However, the majority of tests currently reported
in the literature can only be administered in person dur-
ing the patient's visit and have limited availability. This
limitation does not allow assessment of all cases in home
quarantine, excluding from the objective evaluation the
majority of patients in the initial stages of the disease,
paucisymptomatic or with mild and moderate forms of
COVID-19. To overcome this limitation, we have recently
proposed and validated a new psychophysical test that
can be self-administered by the patient at home.14 The
scoring system of this new test, can produce scores on a
scale of values equal to that provided by the operator-
administered test. For this reason, the results of the two
tests are directly comparable.
In this study, we report and analyze the results of a
large Italian multicenter study that objectively investi-
gated chemoreceptive disorders in COVID-19 patients.
2 | MATERIALS AND METHODS
The multicenter study was conducted in four Italian hos-
pitals: Sassari University Hospital, Salerno University
Hospital, San Paolo Hospital in Milan, Bellaria-Maggiore
Hospital in Bologna.
The olfactory and gustatory functions were objectively
evaluated in two groups of patients:
• Group quarantine: home quarantined health care
workers, with nasopharyngeal swab positive for SARS-
CoV-2 infection.
• Group hospitalized: hospitalized patients with naso-
pharyngeal swab positive for SARS-CoV-2 infection.
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The exclusion criteria for both groups, included:
patients under 18 years of age, psychiatric or neurological
diseases, assisted ventilation or other causes of poor com-
pliance, previous trauma, surgery or radiotherapy in the
oral and nasal cavities, pre-existing test or smell dysfunc-
tions, history of allergic rhinitis or chronic rhinosinusitis.
All patients provided informed consent for participa-
tion in the study. The evaluation protocol was approved
by an independent ethics committee (No. 378-2020-OSS-
AUSLBO).
Preliminarily, some anamnestic data were collected for
all patients in both groups: gender, age, comorbidity or
conditions that could be cause for exclusion, which symp-
toms were seen and when these symptoms started, when
positivity to the first nasopharyngeal swab was confirmed.
Following the criteria proposed by Tian et al15 subjects
were divided into four groups of clinical severity: asymp-
tomatic, mild (mild symptoms, no radiological evidence of
pneumonia), moderate (radiological evidence of pneumo-
nia without dyspnea or respiratory failure), and severe
(radiological evidence of pneumonia with dyspnea and
respiratory failure). All patients were carefully investigated
for any previous or current presence of chemosensitive dis-
orders during the SARS-CoV-2 infection.
2.1 | Group quarantined functional
assessment
The patient cohort was composed of health personnel
(doctors, paramedics, nurses, auxiliary staff) in home
quarantine, after positivity for SARS-CoV-2 confirmed to
the nasopharyngeal swab. This group of patients was
composed both of cases in which the swab was performed
following the onset of suspicious symptoms, and of
asymptomatic patients with positivity detected inciden-
tally to the routine swab.
The patients were contacted by phone, the operator
explained the study methodology and asked the subjects
to collect all the materials necessary for its correct exe-
cution, thus contacting the operator again to perform
the telephone test. The olfactory threshold was deter-
mined using nine solutions with increasing concentra-
tion of denatured ethyl-alcohol. The olfactory
discriminative capability was instead tested by means of
seven groups of odorants, for each of which the patient
expressed an evaluation from 0 (no discrimination) to
10 (normal discrimination). Finally, the gustatory func-
tion was assessed for each of the primary tastes by
means of solutions prepared by the patient.16 The evalu-
ation methodology and the scoring system have been
previously described in detail in the paper in which this
test has been validated.14
2.2 | Group hospitalized functional
assessment
Both the olfactory threshold and the odor discriminative
ability were assessed. All tests were conducted in a quiet
room. Olfactory function assessment was carried out by
means of the Connecticut Chemosensory Clinical
Research Center orthonasal olfaction test (CCCRC).17,18
The CCCRC is a simple, validated and widely used test,
that includes a butanol threshold assessment and a
10-items odor identification test using common odors.
The same standardized and validated test that was used
for the group quarantine, which investigates the ability
to perceive four primary tastes (sweet, salty, sour and
bitter), was performed to evaluate the gustatory function.
The evaluation methodology and the scoring system have
been previously described in detail.13
2.3 | Data analysis
The two tests provide standardized data on the same
evaluation scale of the olfactory and gustatory func-
tion. For this reason, the data of the two groups
were then analyzed together to obtain comparable
information based on the stage of the disease and the
characteristics of the patients. Statistical analysis was
performed using SPSS 26.0 (IBM, Armonk, New York).
Categorical variables are reported in numerals and
percentages of the total. Descriptive statistics for
TABLE 1 General and clinical features of the study
population
No. of patients
Group quarantine 161 (46.7%)





Age (years) 48.5 ± 12.8 (range 23-88)
Days from COVID-19
symptoms onset
14.8 ± 7.4 (range 2-35)
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quantitative variables are given as the mean ± SD
(SD). The statistical analysis of differences in olfactory
and gustatory function, between population sub-
groups, was performed using Mann-Whitney U test
and Kruskal-Wallis H test. Fisher's exact test was used to
evaluate frequency differences. The level of statistical sig-
nificance was set at P ≤ .05 with a 95% confidence
interval.
TABLE 2 Chemosensitive self-reported and objective findings
Objective evaluation results No. of patients (%) Fisher's exact test
Olfactory function
Normal 104 (30.1%)
Mild hyposmia 76 (22%)
Moderate hyposmia 59 (17.1%) P = .000




Mild hypogeusia 78 (22.6%)
Moderate hypogeusia 25 (7.2%)
Severe hypogeusia 16 (4.6%) P = .000
Ageusia 36 (10.4%)
Referred chemosensory dysfunctions
Olfactory and taste disorders 203 (58.8%)
Isolated olfactory disorder 22 (6.4%)
Objective normal 17 (77.3%)
Objective mild hypogeusia 4 (18.2%) P = .024
Objective moderate hypogeusia 1 (4.5%)
Isolated taste disorder 31 (9%)
Objective normal olfaction 21 (67.7%)
Objective mild hyposmia 10 (32.3%) P = .000
Total 256 (74.2%) P = .000
No chemosensitive disorders 89 (25.8%)
Objective normal taste 89 (100%) P = 1.000
Objective normal olfaction 62 (69.7%)
Objective mild hyposmia 27 (30.3%) P = .000
Referred chemosensory recovery
Olfactory recovery (N = 225) 70 (31.1%)
Objective normal 21 (30%)
Objective mild hyposmia 39 (55.7%) P = .000
Objective moderate hyposmia 10 (14.2%)
Taste recovery (N = 234) 118 (50.4%)
Objective normal 84 (71.2%)
Objective mild hypogeusia 29 (24.6%) P = .000
Objective moderate hypogeusia 5 (4.2%)
Chemosensitive symptom duration (N = 256)
≤7 days 191 (74.6%)
>7 days 65 (25.4%) P = .000
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3 | RESULTS
Three hundred and forty-five COVID-19 patients
(146 males, 199 females, mean age 48.5 years old) who
met the inclusion criteria were enrolled for the study the
University Hospital of Sassari, University Hospital “San
Paolo” of Milan, University Hospital of Salerno and
Bellaria-Maggiore Hospital of Bologna.
The study cohort was composed of 161 patients in
home quarantine, assigned to the quarantine group and
evaluated remotely, and 184 hospitalized patients,
assigned to the hospitalized group and evaluated
directly by the operators in the hospital. Table 1 summa-
rizes patient general characteristics and clinical features
(Table 1). The study included patients in all stages of
clinical severity of the disease: 10 (2.9%) asymptomatic,
168 (48.7%) mild disease, 140 (40.6%) moderate disease,
and 27 (7.8%) severe disease.
Chemosensitive dysfunctions during COVID-19 have
been self-reported by 256 patients (74.2% of the study
population). 79.3% of these patients reported combined
chemosensitive disturbances, 8.6% isolated olfactory dis-
orders and 12.1% isolated taste disorders. At the time of
the test, the disorder was self-reported as completely
regressed in 31.3% of the patients with regard to the
sense of smell and in 50.4% for the taste. The objective
results derived from the olfactory and gustatory assess-
ments of the two study groups were analyzed together.14
A framework summary of the data obtained is reported
in Table 2.
3.1 | Olfactory function evaluation
results
Sixty-five percentage of patients reported having had olfac-
tory disorders during the infection (Table 2). However, the
evaluation of patients who reported isolated taste disorders
or no dysfunction, revealed the presence ofmild hyposmia in
an additional 10.7% of patients (P = .000). Furthermore, 70%
of patients who reported complete resolution, proved hyp-
osmic to objective test (P = .000). The analysis of the study
population subgroups, selected according to the disease dura-
tion, showed a high frequency of olfactory disorders through-
out the observation period, ranging between 77.4% (day 1-4)
and 69.2% (day 25-35) (Figure 1). In the early stages, severe
dysfunctions (ie, anosmia or severe hyposmia) affected 70.9%
of patients. Starting from day 10, most of the dysfunctions
FIGURE 1 Olfactory disorders: sub-group analysis [Color figure can be viewed at wileyonlinelibrary.com]
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were instead represented by mild and moderate hyposmias
(Figure 1). The average olfactory score improved rapidly in
the first 10 days, reaching moderate hyposmia values that
weremaintained for the rest of the observation period.
3.2 | Gustatory function evaluation
results
Overall, 234 patients (67.8%) reported having or having
had gustatory disorders during SARS-CoV-2 infection
(Table 2). At the time of the examination, based on the
taste scores obtained, ageusia was detected in 36 cases
(10.4%), 119 patients were seen mild, moderate, or
severe hypogeusia (34.5%) while in 190 cases (55.1%)
the gustatory function was normal. Residual hyp-
ogeusia was detected in 28.8% of patients who reported
complete taste recovery (Table 2). The study of gusta-
tory function in groups of patients in different stages of
the disease, revealed a significant reduction of taste dis-
orders starting on day 10 to 14, with an average taste
score that returns, in the third week, to substantially
normal values (Figure 2).
3.3 | Statistical analysis results
No significant correlation was found between the gusta-
tory and olfactory scores and the gender or age of the
patients (Table 3). Both the olfactory (P = .000) and
gustatory (P = .001) scores showed statistically signifi-
cant differences between subpopulations selected on
the duration of the disease. A more detailed analysis
showed that the improvement in the scores is signifi-
cant between the first and second week (both olfaction
and taste P = .000) of disease, but not between the sec-
ond and third (olfaction P = .119, taste P = .632). No
statistically significant correlation was found between
the COVID-19 severity and the presence or extent of
chemosensitive disorders (Table 4). On the contrary, a
duration of chemosensitive symptoms greater than
7 days, showed a statistically significant correlation
(P = .000) with the development of moderate (relative
risk 1.12) and severe (relative risk 2.33) COVID-19. The
latter analysis was performed only on patients with a
disease duration of more than 14 days, as the first
2 weeks coincides with the higher risk period for respi-
ratory deterioration.1
FIGURE 2 Gustatory disorders: sub-group analysis [Color figure can be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
Chemosensitive disorders are recently emerging as highly
prevalent symptoms during COVID-19.4-10 The studies pub-
lished in the last few weeks are mostly anamnestic and do
not provide an objective quantification of the problem.4-11
The studies that subject patients to psychophysical tests are
few and based on the analysis of small case series and of
patients in late stages of the infection.13,19 The lack of objec-
tive data quantifying the extent of the problem, has meant
that in many countries chemosensitive disorders have not
yet been included in the COVID-19 guidelines.
TABLE 3 General statistical analysis results
No. of patients Olfactory score, mean ± SD Taste score, mean ± SD
Gender
Male 146 (42.3%) 58.9 ± 32.6 2.9 ± 1.4
Female 199 (57.7%) 60.9 ± 31.7 3.1 ± 1.2
Mann-Whitney U-test P = .543 P = .085
Age
≤50 years 204 (59.1%) 61 ± 33.1 3 ± 1.3
>50 years 141 (40.9%) 58.7 ± 30.6 3.1 ± 1.2
Mann-Whitney U-test P = .333 P = .856
Days from symptoms onset Mann-Whitney U test
Olfaction Taste
1-7 days 70 (20.3%) 37.3 ± 36.4 1.9 ± 1.7 P = .000 P = .000
8-14 days 116 (33.6%) 68.4 ± 28.6 3.2 ± 1.2
P = .119 P = .632
>14 days 159 (46.1%) 64.1 ± 27.7 3.4 ± 0.8
Kruskal-Wallis H test P = .000 P = .000
TABLE 4 Clinical statistical analysis results
COVID-19 severity No. of patients Olfactory score, mean ± SD Taste score, mean ± SD
Mann-Whitney U test
Olfaction Taste
Mild disease 168 (48.7%) 54.5 ± 35.3 2.8 ± 1.6 P = .052 P = .103
Moderate disease 115 (33.3%) 64.5 ± 27.2 3.3 ± 1
P = .575 P = .619
Severe disease 52 (15.1%) 61.3 ± 27.9 3.3 ± 0.9
Kruskal-Wallis H test P = .154 P = .112
Type of chemosensitive disorder
Mild
disease (N = 168)
Moderate
disease (N = 115)
Severe





100 (59.5%) 71 (61.7%) 32 (61.5%) P = .941
Taste disorder (N = 234) 118 (70.2%) 82 (71.3%) 34 (65.4%) P = .730
Olfactory disorder (N = 225) 112 (66.6%) 77 (67%) 36 (69.2%) P = .974
Duration of chemosensitive
symptoms (N = 119)*
Mild
disease (N = 20)
Moderate
disease (N = 69)
Severe
disease (N = 30)
Fisher's
exact test
≤7 days 16 (80%) 48 (69.6) 9 (30%) P = .000
>7 days 4 (20%) 21 (30.4%) 21 (70%)
Relative risk RR 1.12 RR 2.33
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The analysis of our case history confirmed a high inci-
dence of chemosensitive disorders during SARS-CoV-2
infection. 74.2% (256 subjects) of patients reported
experiencing or having experienced a chemosensitive dis-
order during the course of the infection. This data is con-
sistent with what has been found in other anamnestic
studies.6,9,10 However, the objective analysis of patients
who did not report taste and smell disturbances, showed
mild hyposmia in 30.3% of cases. Moreover, patients with
subjectively reported isolated dysfunctions of taste or
smell, on psychophysical tests presented with associated
hyposmia or hypogeusia in 32.3% (P = .000) and 22.7%
(P = .024) of the cases, respectively. Anamnestic and
interview studies may therefore underestimate the fre-
quency of these disorders.
The clinical onset of chemosensitive disorders occurs
characteristically in the very early stages of the symptom-
atic infection, generally in the first 3 days. Interestingly,
chemosensitive symptoms were the first symptom of
COVID-19 in 29.2% of patients and the only one in 9.5%
of the cases. According previous studies,4-11,13,14,19 no cor-
relation was found between olfactory and gustatory disor-
ders and nasal obstruction or rhinitis symptoms, present
only in 7.8% of evaluated patients.
The possibility to perform psychophysical tests
remotely, made it possible to evaluate home-quarantined
patients in very early stages of infection, when chemore-
ceptive symptoms were most prevalent. In the first 4 days
from the clinical onset, the frequency of severe chemo-
sensitive disorders was very high, reaching a rate of 71%
for anosmia and severe hyposmia (Figure 1) and 64.5%
for ageusia and severe hypoageusia (Figure 2).
As reported by patients, chemosensitivity recovery
occurred in less than 7 days in 74.6% of cases (P = .000).
However, the evaluation of these patients revealed resid-
ual mild or moderate hyposmia in 69.9% (P = .000) and
mild or moderate hypogeusia in 28.8% (P = .000) of cases.
This difference, already found in the preparatory evalua-
tions for this study13,14 could be related to the presence of
a mild previous disturbance, or to the fact that the patient
had noticed such a great improvement, compared to the
condition of ageusia and/or anosmia that he had suf-
fered, to consider his current chemoreceptive capacity as
normal. Intercepting these residual disturbances is
impossible with the studies based on interviews publi-
shed so far which, also for this reason, underestimate the
extent of these symptoms. From the analysis of the data
of this case series, the average taste and smell scores have
gradually improved in the first 15 days, reaching average
values that do not vary significantly in the subsequent
observation periods (Figures 1 and 2). The recovery of the
gustatory function was more effective and at 15 days the
average score returned to the normal range (Figure 2). In
contrast, the average olfactory score improved significantly
in the first 2 weeks without returning to normal values,
but always remaining in the range of hyposmia, even in
the group of patients evaluated in the third and fourth
week from the clinical onset (Figure 1). The statistical
analysis confirmed the significance of the correlation
between gustatory and olfactory scores and the duration
from the beginning of the disease (Table 3). It is important
to underline that the frequency of severe anosmia and
hyposmia was also significant in the groups of patients
evaluated in the third and fourth week (Figure 1). Obvi-
ously, there is potential for later recovery but the implica-
tion of 25% long term anosmia and severe hyposmia, given
the high incidence of infection globally, means that there
will be a significant number of patients with long term
morbidity. It has implications in that we should be looking
to trial potential treatments in this cohort, starting from
day 14 onwards, which also coincides with the end of
high-risk period for respiratory deterioration.
Moreover, the clinical findings of this study allow us
to orient ourselves among the pathogenetic hypotheses
that we have recently proposed.20 The general tendency
to an albeit partial remission and the relative infre-
quency of other neurological symptoms, tends to
exclude a pathogenesis linked to the invasion of the cen-
tral nervous system through the olfactory pathway and
subsequent neuronal death, as hypothesized by several
authors,9,10 at least in the majority of patients. A recent
experimental study demonstrates that in mouse and in
human olfactory mucosa, COVID-19 virus links
angiotensin-2 converting enzyme (ACE2) receptors
which are expressed in support cell, stem cell and peri-
vascular cell of the olfactory epithelium, but neither in
sensory and olfactory bulbar neurons.21 The infection of
these supporting cells may than affect negatively the
function of olfactory neurons. Moreover, the infection of
basal cells, precursors of the olfactory epithelium recep-
tors, could block or slow down sensory cell turnover
which normally lasts 28 to 30 days.22 This hypothesis
would justify the detection of a high frequency of olfac-
tory disorders 3 to 4 weeks after clinical onset. The full
functional recovery could be reached later, more than a
month not from the beginning of the disease but from
the end of the infection.
As regard taste dysfunction pathogenesis, it is well
known that ACE2-inhibitors can induce ageusia with a
complex mechanism which involves G-protein-coupled
protein and sodium channel present in the taste buds.23
The SARS-CoV-2, infecting the cells and binding these
receptors, could inactivate these latter, blocking the
transformation of chemical gustatory signals into action
potential and consequently the sensory perception of
taste. The rapid recovery of gustatory disorders found in
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COVID-19 patients, can be linked to the rapid turnover
of the taste receptor cells which is only 7 to 10 days.24
The results of the chemosensory evaluation in the
10 asymptomatic patients of this case series are very
important to hypothesize the usefulness of gustatory or
olfactory deficits as screening markers for SARS-CoV-2
infection. Based on a series of 154 COVID-19 patients,
Wee et al25 concluded that self-reported olfactory and
taste disorders had 95.5% specificity and 22.7% sensitivity
as a screening criterion for COVID-19. The olfactory
threshold, widely increased also in the paucisymptomatic
patients of our series, could represent a criterion that
would increase the sensitivity of chemoreceptive disor-
ders as screening for SARS-CoV-2 infection. Moreover,
all asymptomatic patients in our series presented an
olfactory threshold at the lower limits of the norm (ie,
they perceived the dilution N = 6). All patients in this
cohort were in home quarantine and the test performed
remotely tends to slightly overestimate the olfactory
threshold which is then compensated by a more critical
assessment of the discriminative ability compared to the
CCCRC test.14 If evaluated by the operator, these patients
would have presented a slightly hyposmic threshold. In
these days, we are testing the olfactory threshold on all
the staff of the University Hospital of Sassari before the
execution of routine control nasopharyngeal swabs. The
results of this study will give us more precise information
regarding the validity of chemosensitive disorders as a
screening marker. However, on the basis of the results
obtained from this case series, we can conclude that the
sudden reduction in taste and/or smell, even if not associ-
ated with any other symptom, must be considered
strongly suspected for an ongoing SARS-CoV-2 infection.
The significance of chemosensitive disorders as a
prognostic factor remains controversial. Analyzing self-
reported data from 169 COVID-19 patients, Yan et al26
concluded that olfactory loss is associated with a milder
clinical course. However, in studies reliant on self-
reported loss, chemosensitive disorders may simply be
overlooked or forgotten in the setting of severe disease,
ventilatory support, and prolonged recovery. On the basis
of the objective results of our study there is no correlation
between the frequency and extent of chemosensitive dis-
orders and the severity of the disease (Table 4). For this
reason, we can conclude that the chemosensitive symp-
toms during COVID-19 should not be overlooked as they
are not signs of milder forms. In fact, on the contrary, a
statistically significant correlation was found between the
self-reported duration of the chemosensitive disturbances
and the clinical picture severity. Patients who reported a
symptom duration of more than 7 days, have a 2.33 times
greater risk of developing severe forms of COVID-19
(Table 4).
5 | CONCLUSIONS
This study provides further evidence of a high prevalence
of self-reported disturbance of smell and taste in associa-
tion with confirmed COVID-19 infection.
Moreover, this is the first study to report applica-
tion of a home smell and taste test alongside conven-
tion psychophysical testing to determine the severity of
olfactory and gustatory dysfunction in a significant
number of patients. This highlights that patients
under-report the frequency of chemosensitive disor-
ders, Contrary to recent reports, such objective testing
refutes the proposal that the presence of olfactory and
gustatory dysfunction may predict a milder course, but
instead suggests that those with more severe disease
neglect such symptoms in the setting of severe respira-
tory disease.
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